TerrAscend Corp. (“TerrAscend” or the “Company”) (CSE:TER, OTCQX: TRSSF), a leading North American cannabis operator, today announced that TerrAscend NJ, LLC (“TerrAscend NJ”) has been issued a permit to process cannabis by the New Jersey Department of Health (“NJ DOH”) which allows the Company to engage in the extraction, processing and manufacturing of a wide range of branded form factors including, vaporizables, concentrates, topicals, tinctures and edibles under the Ilera Healthcare, Kind Tree, and Prism brands.
“We are pleased to receive our processing permit from the NJ DOH and we look forward to introducing TerrAscend’s house of brands and form factors to medical-use patients through our ATCs1 and the wholesale channel,” said Jason Ackerman, CEO and Executive Chairman of TerrAscend. “Our medical cannabis business in New Jersey is performing well and we are prepared to meet customer demand once adult-use sales are permitted.”
TerrAscend’s 16-acre site is located in Boonton Township in Morris County. Construction of a 140,000 sq. ft. production facility is complete, and the Company has completed several harvests from its 40,000 square foot greenhouse with sales commencing late in the fourth quarter. In addition, the first harvests are currently underway at the Company’s newly completed 80,000 square foot indoor grow facility with first sales into the market anticipated in the coming weeks. The scaled cultivation, processing, and manufacturing capacity of the Boonton facility will allow for the supply of a wide range of branded form factors to TerrAscend’s ATCs, as well as other dispensaries across the state.
The Company is leveraging the strong brand equity and operational expertise of The Apothecarium as its retail banner in New Jersey. The Apothecarium has nine locations in California, Pennsylvania, and New Jersey, and is recognized as one of the nation’s premier chains of dispensaries. The Phillipsburg, New Jersey location is now open and the second Apothecarium branded ATC is expected to open in Maplewood in Q2 2021, followed by an additional ATC in Q3 2021.
In December 2018, TerrAscend applied for one of six permits, out of 146 applications, for a vertically integrated permit to cultivate, process and dispense medical cannabis in the State of New Jersey. Having secured cultivation and dispensing approvals, TerrAscend is now vertically integrated in the highly populous northern New Jersey region where the Company is one of four permittees. Currently a medical-use market, New Jersey recently finalized legislation that legalized adult-use cannabis sales in the state. New Jersey is the 11th largest state in the U.S. with nearly 9 million residents. According to the NJ DOH, as of January 2021, over 100,000 patients have gained access to the state’s medical marijuana program with the highest density of patients concentrated in northern New Jersey. The number of registered medical marijuana patients in the state has quadrupled since the beginning of 2018.
1Alternative Treatment Center
The Canadian Securities Exchange (“CSE”) has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
